Combination Antiretroviral Therapy and Immunophenotype of Feline Immunodeficiency Virus

Feline Immunodeficiency Virus (FIV) causes progressive immune dysfunction in cats similar to human immunodeficiency virus (HIV) in humans. Although combination antiretroviral therapy (cART) is effective against HIV, there is no definitive therapy to improve clinical outcomes in cats with FIV. This study therefore evaluated pharmacokinetics and clinical outcomes of cART (2.5 mg/kg Dolutegravir; 20 mg/kg Tenofovir; 40 mg/kg Emtricitabine) in FIV-infected domestic cats. Specific pathogen free cats were experimentally infected with FIV and administered either cART or placebo treatments (n = 6 each) for 18 weeks, while n = 6 naïve uninfected cats served as controls. Blood, saliva, and fine needle aspirates from mandibular lymph nodes were collected to quantify viral and proviral loads via digital droplet PCR and to assess lymphocyte immunophenotypes by flow cytometry. cART improved blood dyscrasias in FIV-infected cats, which normalized by week 16, while placebo cats remained neutropenic, although no significant difference in viremia was observed in the blood or saliva. cART-treated cats exhibited a Th2 immunophenotype with increasing proportions of CD4+CCR4+ cells compared to placebo cats, and cART restored Th17 cells compared to placebo-treated cats. Of the cART drugs, dolutegravir was the most stable and long-lasting. These findings provide a critical insight into novel cART formulations in FIV-infected cats and highlight their role as a potential animal model to evaluate the impact of cART on lentiviral infection and immune dysregulation.

[1]  Parnian Shobeiri,et al.  T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses , 2021, Transplant Immunology.

[2]  J. Schiffer,et al.  A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir , 2021, Cell reports. Medicine.

[3]  S. Cowan,et al.  A probe-based droplet digital polymerase chain reaction assay for early detection of feline acute cytauxzoonosis. , 2021, Veterinary parasitology.

[4]  A. Perelson,et al.  CD8 Lymphocyte Depletion Enhances the Latency Reversal Activity of the SMAC Mimetic AZD5582 in ART-Suppressed Simian Immunodeficiency Virus-Infected Rhesus Macaques , 2021, Journal of Virology.

[5]  J. Safrit,et al.  Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques , 2020, Journal of Virology.

[6]  Kirk A Easley,et al.  Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques , 2020, Journal of Virology.

[7]  Xu G. Yu,et al.  Blood and lymph node dissemination of clonal genome-intact HIV-1 DNA sequences during suppressive antiretroviral therapy. , 2020, The Journal of infectious diseases.

[8]  S. Lewin,et al.  Human Immunodeficiency Virus (HIV)–Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy , 2019, The Journal of infectious diseases.

[9]  M. Lichterfeld,et al.  Pharmacological Modulation of the Wnt/β-Catenin Pathway Inhibits Proliferation and Promotes Differentiation of Long-Lived Memory CD4+ T Cells in Antiretroviral Therapy-Suppressed Simian Immunodeficiency Virus-Infected Macaques , 2019, Journal of Virology.

[10]  J. Lifson,et al.  PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy , 2019, Antimicrobial Agents and Chemotherapy.

[11]  Craig A. Miller,et al.  Immunopathologic Effects of Prednisolone and Cyclosporine A on Feline Immunodeficiency Virus Replication and Persistence , 2019, Viruses.

[12]  F. Ceccherini‐Silberstein,et al.  Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success. , 2019, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  M. Wainberg,et al.  Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes , 2018, Journal of Virology.

[14]  G. Silvestri,et al.  Bone Marrow-Derived CD4+ T Cells Are Depleted in Simian Immunodeficiency Virus-Infected Macaques and Contribute to the Size of the Replication-Competent Reservoir , 2018, Journal of Virology.

[15]  F. Maldarelli,et al.  Quantification of HIV DNA Using Droplet Digital PCR Techniques , 2018, Current protocols in microbiology.

[16]  W. Heneine,et al.  Efficacy of Vaginally Administered Gel Containing Emtricitabine and Tenofovir Against Repeated Rectal Simian Human Immunodeficiency Virus Exposures in Macaques , 2018, The Journal of infectious diseases.

[17]  D. Carnathan,et al.  Antibody-Mediated CD4 Depletion Induces Homeostatic CD4+ T Cell Proliferation without Detectable Virus Reactivation in Antiretroviral Therapy-Treated Simian Immunodeficiency Virus-Infected Macaques , 2018, Journal of Virology.

[18]  Craig A. Miller,et al.  FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge , 2018, npj Vaccines.

[19]  Z. Abdo,et al.  Applications of the FIV Model to Study HIV Pathogenesis , 2018, Viruses.

[20]  C. Power.  Neurologic disease in feline immunodeficiency virus infection: disease mechanisms and therapeutic interventions for NeuroAIDS , 2017, Journal of NeuroVirology.

[21]  J. Clements,et al.  An SIV/macaque model targeted to study HIV-associated neurocognitive disorders , 2018, Journal of NeuroVirology.

[22]  Scott Carver,et al.  Pathogenesis of oral FIV infection , 2017, PloS one.

[23]  J. Hauber,et al.  Assessment of the HIV-1 reservoir in CD4+ regulatory T cells by a Droplet Digital PCR based approach. , 2017, Virus research.

[24]  H. Germain,et al.  Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data , 2017, Scientific Reports.

[25]  W. Heneine,et al.  Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques. , 2015, The Journal of antimicrobial chemotherapy.

[26]  C. Fletcher,et al.  Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  S. Piscitelli,et al.  Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients , 2015, British journal of clinical pharmacology.

[28]  Paweł M. Bęczkowski,et al.  Contrasting clinical outcomes in two cohorts of cats naturally infected with feline immunodeficiency virus (FIV) , 2015, Veterinary microbiology.

[29]  P. L. McCormack.  Dolutegravir: A Review of Its Use in the Management of HIV-1 Infection in Adolescents and Adults , 2014, Drugs.

[30]  Jinyan Liu,et al.  Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys , 2014, Nature.

[31]  M. Goldman,et al.  Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  R. Rathbun,et al.  Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection , 2014, The Annals of pharmacotherapy.

[33]  R. Schinazi,et al.  Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells. , 2014, American journal of veterinary research.

[34]  A. Kashuba,et al.  Single and Multiple Dose Pharmacokinetics of Dolutegravir in the Genital Tract of HIV-Negative Women , 2013, Antiviral therapy.

[35]  N. Shaheen,et al.  Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV-Negative Men After Single and Multiple Dosing , 2013, Journal of acquired immune deficiency syndromes.

[36]  Christopher M. Hindson,et al.  Absolute quantification by droplet digital PCR versus analog real-time PCR , 2013, Nature Methods.

[37]  P. Cahn,et al.  Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study , 2013, The Lancet.

[38]  K. S. Coats,et al.  Aberrant placental immune parameters in the feline immunodeficiency virus (FIV)-infected cat suggest virus-induced changes in T cell function , 2013, Virology Journal.

[39]  Douglas D. Richman,et al.  Highly Precise Measurement of HIV DNA by Droplet Digital PCR , 2013, PloS one.

[40]  G. di Perri,et al.  Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function , 2013, Antimicrobial Agents and Chemotherapy.

[41]  K. Hartmann.  Clinical Aspects of Feline Retroviruses: A Review , 2012, Viruses.

[42]  N. Gómez,et al.  Evaluation of Different Antiretroviral Drug Protocols on Naturally Infected Feline Immunodeficiency Virus (FIV) Cats in the late Phase of the Asymptomatic Stage of Infection , 2012, Viruses.

[43]  Martha MacMillan,et al.  Pathogenicity and Rapid Growth Kinetics of Feline Immunodeficiency Virus Are Linked to 3′ Elements , 2011, PloS one.

[44]  K. S. Coats,et al.  Cytokine Dysregulation in Early‐ and Late‐Term Placentas from Feline Immunodeficiency Virus (FIV)‐Infected Cats , 2011, American journal of reproductive immunology.

[45]  A. Luster,et al.  CXCR3 in T cell function. , 2011, Experimental cell research.

[46]  S. Piscitelli,et al.  Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.

[47]  M. Hollenberg,et al.  CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  K. Hartmann,et al.  Hematology and serum biochemistry of feline immunodeficiency virus-infected and feline leukemia virus-infected cats. , 2009, Journal of veterinary internal medicine.

[49]  Chun-Peng Liao,et al.  Identification of a novel common proviral integration site, flit-1, in feline leukemia virus induced thymic lymphoma. , 2009, Virology.

[50]  S. Gaffen,et al.  Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis , 2009, The Journal of experimental medicine.

[51]  Sue VandeWoude,et al.  Prevention of immunodeficiency virus induced CD4+ T-cell depletion by prior infection with a non-pathogenic virus. , 2008, Virology.

[52]  W. Tompkins,et al.  Lentivirus-induced immune dysregulation. , 2008, Veterinary immunology and immunopathology.

[53]  J. Farber,et al.  Human T Cells That Are Able to Produce IL-17 Express the Chemokine Receptor CCR61 , 2008, The Journal of Immunology.

[54]  F. van der Meer,et al.  Comparative evaluation of the activity of antivirals towards feline immunodeficiency virus in different cell culture systems. , 2007, Antiviral research.

[55]  M. Pistello,et al.  Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS , 2007, Retrovirology.

[56]  D. Jarrossay,et al.  Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells , 2007, Nature Immunology.

[57]  M. Lederman,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Nature Medicine.

[58]  D. Douek,et al.  HIV disease: fallout from a mucosal catastrophe? , 2006, Nature Immunology.

[59]  W. Tompkins,et al.  Preferential Feline Immunodeficiency Virus (FIV) Infection of CD4+ CD25+ T-Regulatory Cells Correlates both with Surface Expression of CXCR4 and Activation of FIV Long Terminal Repeat Binding Cellular Transcriptional Factors , 2005, Journal of Virology.

[60]  F. Rousseau,et al.  Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.

[61]  Christine Hogan,et al.  Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[62]  Antonio Lanzavecchia,et al.  Chemokine Receptor Expression Identifies Pre–T Helper (Th)1, Pre–Th2, and Nonpolarized Cells among Human CD4+ Central Memory T Cells , 2004, The Journal of experimental medicine.

[63]  E. Hoover,et al.  Characterization of a Highly Pathogenic Molecular Clone of Feline Immunodeficiency Virus Clade C , 2004, Journal of Virology.

[64]  E. Hoover,et al.  Gamma Interferon/Interleukin 10 Balance in Tissue Lymphocytes Correlates with Down Modulation of Mucosal Feline Immunodeficiency Virus Infection , 2004, Journal of Virology.

[65]  W. Tompkins,et al.  Preferential replication of FIV in activated CD4(+)CD25(+)T cells independent of cellular proliferation. , 2004, Virology.

[66]  W. Tompkins,et al.  Failure of FIV-infected cats to control Toxoplasma gondii correlates with reduced IL2, IL6, and IL12 and elevated IL10 expression by lymph node T cells. , 2004, Veterinary immunology and immunopathology.

[67]  F. Sallusto.  The role of chemokine receptors in primary, effector and memory immune response , 2002 .

[68]  J. Kahn,et al.  Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults , 2001, Antimicrobial Agents and Chemotherapy.

[69]  W. Tompkins,et al.  Constitutive expression of types 1 and 2 cytokines by alveolar macrophages from feline immunodeficiency virus-infected cats , 2001, Veterinary Immunology and Immunopathology.

[70]  M. A. McCrackin Stevenson,et al.  In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants. , 2001, American journal of veterinary research.

[71]  A. Berger.  Th1 and Th2 responses: what are they? , 2000, BMJ : British Medical Journal.

[72]  E. Hoover,et al.  Feline immunodeficiency virus clade C mucosal transmission and disease courses. , 2000, AIDS research and human retroviruses.

[73]  N. Pedersen,et al.  Cytokine Response in Multiple Lymphoid Tissues during the Primary Phase of Feline Immunodeficiency Virus Infection , 1998, Journal of Virology.

[74]  C. Mackay,et al.  Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. , 1998, Immunology today.

[75]  W. Tompkins,et al.  Elevated interleukin-10-to-interleukin-12 ratio in feline immunodeficiency virus-infected cats predicts loss of type 1 immunity to Toxoplasma gondii. , 1998, The Journal of infectious diseases.

[76]  K. Hartmann,et al.  Feline immunodeficiency virus infection: an overview , 1998, The Veterinary Journal.

[77]  R. Schinazi,et al.  A Novel Point Mutation at Position 156 of Reverse Transcriptase from Feline Immunodeficiency Virus Confers Resistance to the Combination of (−)-β-2′,3′-Dideoxy-3′-Thiacytidine and 3′-Azido-3′-Deoxythymidine , 1998, Journal of Virology.

[78]  R. Schinazi,et al.  A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides , 1997, Journal of virology.

[79]  E. De Clercq,et al.  Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice , 1997, Antimicrobial agents and chemotherapy.

[80]  G. Hoffmann-Fezer,et al.  Comparison of T-cell subpopulations in cats naturally infected with feline leukaemia virus or feline immunodeficiency virus. , 1996, Research in veterinary science.

[81]  B. Willett,et al.  A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction , 1996, Journal of virology.

[82]  E. Hoover,et al.  Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage , 1995, Journal of virology.

[83]  J. Meers,et al.  Quantification of lymphadenopathy in experimentally induced feline immunodeficiency virus infection in domestic cats. , 1995, Veterinary immunology and immunopathology.

[84]  E. De Clercq,et al.  (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection , 1995, Antimicrobial agents and chemotherapy.

[85]  I. Nolte,et al.  Hemostatic Disorders in Feline Immunodeficiency Virus‐Seropositive Cats , 1994, Journal of veterinary internal medicine.

[86]  G. Hoffmann-Fezer,et al.  Decline in CD4+ cell numbers in cats with naturally acquired feline immunodeficiency virus infection , 1992, Journal of virology.

[87]  N. Pedersen,et al.  Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus , 1990, Journal of virology.

[88]  S. Crispin,et al.  Clinical and laboratory findings in cats infected with feline immunodeficiency virus , 1989, Veterinary Record.

[89]  N. Pedersen,et al.  Feline Immunodeficiency Virus Infection , 2013, Canine and Feline Infectious Diseases.

[90]  N. Pedersen,et al.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. , 1987, Science.

[91]  J. Neil,et al.  Infection with feline immunodeficiency virus is followed by the rapid expansion of a CD8+ lymphocyte subset. , 1993, Immunology.